Файл: ВГ С gastroe.ru ropip_rekomendatsii_po_lecheniu_gepatitac_2017.pdf

121.Sherman K..E.. et al.. Response-guided telaprevir combination treatment for hepatitis C virus infection // N.. Engl.. J.. Med.. — 2011.. — Vol.. 365.. — P.. 1014–1024. — Erratum in.. P.. 1551..

122.Suda G.. et al.. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C // J.. Gastroenterol.. — 2016 Jul. — Vol.. 51(7).. — P.. 733–740..

123.Sulkowski M..S.., Gardiner D..F.., Rodriguez T..M.., et al.. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection // N.. Engl.. J.. Med.. — 2014.. — Vol.. 370(3).. — P.. 211–221..

124.Tong X. . et al. . Preclinical Characterization of the Antiviral Activity of SCH 900518 (Narlaprevir), a Novel Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease // Antimicrob.. Agents Chemother.. — 2010.. — Vol.. 54.. — P.. 2365–2370..

125.Toyoda H.. et al.. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis // J.. Gastroenterol.. — 2016 Jul.. — Vol.. 51(7).. — P.. 741–747..

126.Vierling J.. et al.. Once daily Narlaprevir (NVR; SCH 900518) and Ritonavir (RTV) in combination with peginterferon alfa-2b/ribavirin (PR) for 12 weeks plus 12 weeks PR in treatment-naive patients with HCV genotype 1 (G1): SVR results from NEXT-1, a phase 2 study // Hepatology.. — 2011.. — Vol.. 54.. — P.. 1439A..

127.Waldenström J. ., Färkkilä M. ., Rembeck K. . et al. . Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience // Scand.. J.. Gastroenterol.. — 2016 Mar.. — Vol.. 51(3).. — P.. 337–343.. — doi: 10..3109/00365521..2015..1087588..

128.Welzel T..M.., Nelson D..R.., Morelli G.. et al.. Safety and Efficacy of Sofosbuvir and Ribavirin for the Treatment of HCV Genotype 2 and 3: Results of the HCV-TARGET Study.. — Poster 1057.. — Paper presented at: American Association for the Study of Liver Diseases (AASLD); 13–17 November, 2015; San Francisco, CA..

129.Wetzel T..M.. et al.. Daclatasvir Plus Sofosbuvir With or Without Ribavirin for Treatment of Chronic HCV Infection in Patients With Advanced Liver Disease: Results of a European Compassionate 30..

130.World Health Assembly (Sixty-ninth, May 2016).. — http://www..who..int/mediacentre/ events/2016/wha69/en

131.Zarski J..P.., Sturm N.., Guechot J.. et al.. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study // J. Hepatol.. — 2012.. — Vol.. 56.. — N 1.. — P.. 55–62..

132.Zeuzem S. ., Dusheiko G. .M. ., Salupere R. ., Mangia A. ., Flisiak R. ., Hyland R. .H. . et al.. Sofosbuvir and ribavirin in HCV genotypes 2 and 3.. N.. Engl.. J.. Med.. — 2014.. — Vol. 370. — P.. 1993–2001..

133.Znoyko O. ., Maevskaya M. ., Klimova E. . et al. . Early virologic response (EVR) in treatment-naive mono-infected chronic hepatitis C (CHC) patients treated with cepeginterferon-alfa-2b (cePEG-IFNa-2b) plus ribavirin. . Journal of Hepatology. — 2013.. — Vol.. 58, Suppl.. 1.. — P.. 348–349..

134.Znoyko O.., Mayevskaya M..V.., Klimova E.. et al.. Rapid and early virologic response to сepeginterferon-alfa-2b in combination with ribavirine in treatment-naïve patients with chronic HCV // Hepatology.. — October 2012.. — Vol.. 56.. — N 4 (suppl..).. — P.. 586A..

135.Zuckerman E. ., Ashkenasi E. ., Kovalev Y. . et al. . The real-world Israeli experience of treating chronic hepatitis C, genotype 1 patients with advanced fibrosis with

paritaprevir/ritonavir/ombitasvir, dasabuvir with or without ribavirin: a large multicenter J. Hepatol.. — 2016.. Vol.. 64(2).. — S137; PS004..

136.. http://www..hep-druginteractions..org..